Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies.

导出 LinkOut

翻译打印收藏纠错

第一作者： M C,Hochberg

第一单位： Departments of Medicine and Epidemiology and Public Health, University of Maryland School of Medicine and the Medical Care Clinical Center, VA Maryland Health Care System, Baltimore, MD, USA. Electronic address: mhochber@medicine.umaryland.edu.

作者： M C,Hochberg ^[1]

作者单位： Departments of Medicine and Epidemiology and Public Health, University of Maryland School of Medicine and the Medical Care Clinical Center, VA Maryland Health Care System, Baltimore, MD, USA. Electronic address: mhochber@medicine.umaryland.edu. ^[1]

关键词 Fulranumab Monoclonal antibodies to nerve growth factor Osteonecrosis Rapidly progressive osteoarthritis Tanezumab

主题词抗体, 单克隆(Antibodies, Monoclonal);人类(Humans);关节疾病(Joint Diseases);神经生长因子(Nerve Growth Factor);骨坏死(Osteonecrosis);随机对照试验(主题)(Randomized Controlled Trials as Topic)

DOI 10.1016/j.joca.2014.10.005

PMID 25527216

发布时间 2022-03-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交